ABSTRACT

Falsified drugs pose a challenge to public health in the case of serious adverse effects, the association of harmful ingredients with other medicines, little change in the disincentive of health conditions to take prescription medicines and lack of confidence in the health care system. There is no system at present that helps consumers to check where a drug comes from The EU Falsified Medicines Directive (FMD) aims to prohibit falsified medicines from accessing and reaching patients in the legal supply chain. This impact review acknowledges the versatility of Article 23 under the FMD's safety features policy. The policy of "safety characteristics" includes a unique identifier and tamper- evident characteristics to be applied to prescription medicines to prevent damage from falsified drugs to persons in the UK and to decrease the incidence of falsified medicines in the legal supply chain. Keywords: EU FMD, Falsified medicines, Falsified medicines Directive, Safety features, Supply chain
Publication date: 01/11/2021

https://ijbpas.com/pdf/2021/November/MS_IJBPAS_2021_5727.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2021/10.11.5727